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INTRODUCTION 
Drug delivery is often approached via a drug's chemical 
formulation, but it may also involve medical devices or 
drug-device combination products. Drug delivery is a 
concept heavily integrated with dosage form and route of 
administration. These technologies modify drug release 
profile, absorption, distribution and elimination for the 
benefit of improving product efficacy and safety, as well 
as patient convenience and compliance. Drug release is 
from: diffusion, degradation, swelling, and affinity-based 
mechanisms.  
Current efforts in the area of drug delivery include the 
development of targeted delivery in which the drug is 
only active in the target area of the body (for example, in 
cancerous tissues) and sustained release formulations in 
which the drug is released over a period of time in a 
controlled manner from a formulation. In order to 
achieve efficient targeted delivery, the designed system 
must avoid the host's defense mechanisms and circulate 
to its intended site of action. Types of sustained release 
formulations include liposomes, drug loaded 
biodegradable microspheres and drug polymer 
conjugates. 
Skeletal Drug Delivery System: 
Selective drug delivery to any organ becomes very 
important in certain diseases and clinical manifestations, 
especially when the drug affects other exposed tissues 
adversely. The importance of selective drug action is still 
further increased when the affected part is poorly 
perfused. Although a network of blood vessels is present 
throughout skeletal tissue (or bone), it is not sufficient 
for immediate delivery of drugs to the desired site of 
action in the tissue and in sufficient amounts over 
appropriate time periods. Hence, selective drug delivery 
to the skeletal system has remained a great challenge to 
pharmaceutical scientists over the years. However, in the 
recent past, attention has been focused on the importance 
of skeletal drug delivery and the first Skeletal Drug 
Delivery System (SDDS) was introduced by Bucholz and 
Engelbrecht in 1970 for the delivery of drugs to skeletal 
tissues at a high concentration to achieve desirable 
therapeutic effects.1  
Skeletal Drug Delivery and Tissue Engineering: 
Protein and peptide delivery and nanotechnology have 
been applied in skeletal drug delivery (targeting to bones 
and cartilages). Composite tablets, implants, and 
injectable hydrogels composed of biodegradable 
polymers and ceramics are developed as locally deliver 
systems of antibiotics, chemotherapeutic agents, steroids, 
non-steroid anti-inflammatory drugs, etc. Their 
physicochemical characteristics, product stability, 
bioactivities, are characterized. Release profiles, 
antimicrobial activities and biocompatibility of the 
composites are evaluated in vitro. Targeted delivery 
systems of growth factors and protein drugs to bones and 
cartilages may be suitable in to create new tissues from 
the cultured cells. It has been considered as a potential 
alternative to organ or tissue transplantation. 
Biodegradable scaffolds and suitable growth factor 
delivery systems play important roles in transforming the 
cultured cells to new tissues. Modification of material 
surface with cell specificity can be grafted to scaffolds to 
prepare cell specific scaffolds. Cultures of osteoblast-like 
cells and chondrocytes conditioned with controlled 
release delivery systems and suitable therapeutic forms 
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of growth factors can promote cell proliferation and 
differentiation in bone and cartilage tissue engineering. 
Anatomy of Skeletal System: 
Skeletal system is all of the bones in the body and the 
tissues such as tendons, ligaments and cartilage that 
connect them. The skeletal system includes all of the 
bones and joints in the body. Each bone is a complex 
living organ that is made up of many cells, protein fibres, 
and minerals. The skeleton acts as a scaffold by 
providing support and protection for the soft tissues that 
make up the rest of the body. The skeletal system also 
provides attachment points for muscles to allow 
movements at the joints. New blood cells are produced 
by the red bone marrow present inside the bones. Bones 
act as the body’s warehouse for calcium, iron, and 
energy in the form of fat. Finally, the skeleton grows 
throughout childhood and provides a framework for the 
rest of the body to grow along with it. 
Anatomy: 
The skeletal system in an adult body is made up of 206 
individual bones. These bones are arranged into two 
major divisions: the axial skeleton and the appendicular 
skeleton. The axial skeleton runs along the body’s 
midline axis and is made up of 80 bones in the following 
regions: Skull, auditory ossicles, ribs, sternum and 
vertebral column. The appendicular skeleton is made up 
of 126 bones in the regions: upper and lower limbs, 
pelvic and pectoral girdle. 
Microscopic structure of Bone: 
The skeleton makes up about 30-40% of an adult’s body 
mass. The skeleton’s mass is made up of nonliving bone 
matrix and many tiny bone cells. Roughly half of the 
bone matrix’s mass is water, while the other half is 
collagen protein and solid crystals of calcium carbonate 
and calcium phosphate. 
Living bone cells are found on the edges of bones and in 
small cavities inside of the bone matrix. Although these 
cells make up very little of the total bone mass, they have 
several very important roles in the functions of the 
skeletal system2. The bone cells allow bones to: 
 Grow and develop 
 Be repaired following an injury or daily wear 
 Be broken down to release their stored minerals  
Old bones are dead, dry and brittle. But in the body, 
bones are very much alive. They have their own nerves 
and blood vessels, and they do various jobs, such as 
storing body minerals like calcium. Bones are made of a 
mix of hard stuff that gives them strength and tons of 
living cells which help them grow and repair themselves.
  
Skeletal System Physiology: 
 Support and Protection: The skeletal system’s 
primary function is to form a solid framework that 
supports and protects the body's organs and anchors 
the skeletal muscles. The bones of the axial skeleton 
act as a hard shell to protect the internal organs—
such as the brain and the heart—from damage 
caused by external forces. The bones of the 
appendicular skeleton provide support and flexibility 
at the joints and anchor the muscles that move the 
limbs. 
 Movement: The bones of the skeletal system act as 
attachment points for the skeletal muscles of the 
body. Almost every skeletal muscle works by 
pulling two or more bones either closer together or 
further apart.  
 Hematopoiesis: Red bone marrow produces red and 
white blood cells in a process known as 
hematopoiesis. Red bone marrow is found in the 
hollow space inside of bones known as the 
medullary cavity.4  
 Storage: The skeletal system stores many different 
types of essential substances to facilitate growth and 
repair of the body. The skeletal system’s cell matrix 
acts as our calcium bank by storing and releasing 
calcium ions into the blood as needed. Proper levels 
of calcium ions in the blood are essential to the 
proper function of the nervous and muscular 
systems. Bone cells also release osteocalcin, a 
hormone that helps regulate blood sugar and fat 
deposition. The yellow bone marrow inside of our 
hollow long bones is used to store energy in the 
form of lipids. Finally, red bone marrow stores some 
iron in the form of the molecule ferritin and uses this 
iron to form hemoglobin in red blood cells. 
 Growth and Development: The skeleton begins to 
form early in fetal development as a flexible 
skeleton made of hyaline cartilage and dense 
irregular fibrous connective tissue. These tissues act 
as a soft, growing framework and placeholder for 
the bony skeleton that will replace them. As 
development progresses, blood vessels begin to 
grow into the soft fetal skeleton, bringing stem cells 
and nutrients for bone growth. Osseous tissue slowly 
replaces the cartilage and fibrous tissue in a process 
called calcification. The calcified areas spread out 
from their blood vessels replacing the old tissues 
until they reach the border of another bony area.   
Disorders of skeletal system: 
1. Osteoporosis: 
Osteoporosis is a disease of the bones, due to loss of 
bone or very little bone or both. Osteoporosis means 
―porous bone‖. A healthy bone observed under a 
microscope, parts of bone look like a honeycomb. If 
bone of a person suffering from osteoporosis is examined 
under a microscope, the holes and spaces in the 
honeycomb are much bigger than they are in healthy 
bone. This means bones have lost density or mass 
and that the structure of bone tissue has become 
abnormal. If bones become less dense, they also become 
weaker and more likely to break. Nearly 60% of adults 
age 50 and older are at risk of breaking a bone and 
should be concerned about bone health. Studies also 
suggest that approximately one in two women and up to 
one in four men age 50 and older will break a bone due 
to osteoporosis. 
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Osteoporosis is often called the ―silent disease," because 
people could have it now or be at-risk without even 
realizing it. Osteoporosis affects men and women of all 
races. But white and Asian women especially those who 
are past menopause are at highest risk. Medications, 
healthy diet and weight-bearing exercise can help 
prevent bone loss or strengthen already weak bones.  
2. Bursitis: 
Bursitis is the inflammation of one or more bursae (small 
sacs) of synovial fluid in the body. Healthy bursae create 
a smooth, almost frictionless functional gliding surface 
making normal movement painless. When bursitis 
occurs, however, movement relying upon the inflamed 
bursa becomes difficult and painful. Moreover, 
movement of tendons and muscles over the inflamed 
bursa aggravates its inflammation, perpetuating the 
problem. Muscle can also be stiffened. Bursitis is 
commonly caused by repetitive movement and excessive 
pressure. Shoulders, elbows and knees are the most 
commonly affected. Traumatic injury is another cause of 
bursitis. The inflammation irritates because the bursa no 
longer fits in the original small area between the bone 
and the functionary muscle or tendon.  
3. Osteoarthritis: 
Osteoarthritis (OA) also known as degenerative arthritis 
or degenerative joint disease or osteoarthrosis, is a group 
of mechanical abnormalities involving degradation of 
joints, including articular cartilage and subchondral 
bone. Symptoms may include joint pain, tenderness, 
stiffness, locking, and sometimes an effusion. A variety 
of causes—hereditary, developmental, metabolic, and 
mechanical deficits—may initiate processes leading to 
loss of cartilage. When bone surfaces become less well 
protected by cartilage, bone may be exposed and 
damaged. As a result of decreased movement secondary 
to pain, regional muscles may atrophy, and ligaments 
may become more lax.  
4. Osteomyelitis: 
Osteomyelitis (sometimes abbreviated to OM, and 
derived from Greek words osteon, meaning bone, myelo- 
meaning marrow, and -itis meaning inflammation) is 
infection and inflammation of the bone or bone marrow. 
It can be usefully sub-classified on the basis of the 
causative organism (pyogenic bacteria or mycobacteria), 
the route, duration and anatomic location of the 
infection.3 
5. Paget’s Disease: 
Paget's disease of bone is a chronic disorder that can 
result in enlarged and misshapen bones. Paget's is caused 
by the excessive breakdown and formation of bone, 
followed by disorganized bone remodeling. This causes 
affected bone to weaken, resulting in pain, misshapen 
bones, fractures, and arthritis in the joints near the 
affected bones. Paget's disease typically is localized, 
affecting just one or a few bones, as opposed to 
osteoporosis, for example, which usually affects all the 
bones in the body.5 
DRUGS INCORPORATED IN SKELETAL DRUG 
DELIVERY DEVICES/SYSTEM: 
1. Norfloxacin: 
Norfloxacin is a synthetic chemotherapeutic antibacterial 
agent. In form of ophthalmic solutions it is known as 
Chibroxin. Norfloxacin is a first generation synthetic 
fluoroquinolone (quinolone) developed by Kyorin 
Seiyaku K.K. (Kyorin).5 Norfloxacin interacts with a 
number of other drugs, as well as a number of herbal and 
natural supplements. Such interactions increase the risk 
of anticoagulation and the formation of non-absorbable 
complexes, as well as increasing the risk of toxicity.  
Norfloxacin is a broad-spectrum antibiotic that is active 
against both Gram-positive and Gram-negative bacteria. 
It functions by inhibiting DNA Gyrase, a type II 
topoisomerase, and topoisomerase IV,enzymes necessary 
to separate bacterial DNA, thereby inhibiting cell 
division.6,7 
2. Cefalexin: 
Cefalexin (INN) or more commonly cephalexin is a first-
generation cephalosporin antibiotic introduced in 1967 
by Eli Lilly and Company. It is an orally administered 
agent with a similar antimicrobial spectrum to the 
intravenous agents cefalotin and cefazolin. It was first 
marketed as Keflex (Lilly), and is marketed under 
several other trade names. Cefalexin is used to treat a 
number of infections including: otitis media, 
streptococcal pharyngitis, bone and joint infections, 
pneumonia, cellulitis, and urinary tract infections.  
3. Samarium-153: 
Samarium-153 is an isotope of samarium. It emits beta 
particles and gamma rays. The therapeutic component is 
largely due to the beta particles, but the gamma rays 
make it easier to locate the distribution. It is used in 
samarium (153Sm) lexidronam. It is treated by the body in 
a similar manner to calcium, and it localizes selectively 
to bone. It is used in palliation of bone cancer. 
4. Samarium(153Sm) Lexidronam: 
Samarium (153Sm) lexidronam (chemical name 
Samarium-153-ethylenediaminetetramethylene 
phosphonate, abbreviated Samarium-153 EDTMP, trade 
name Quadramet) is a complex of a radioisotope of the 
lanthanideelementsamarium with the chelator EDTMP. It 
is used to treat pain when cancer has spread to the bone. 
8,9,10, 11 It is injected into a vein and distributed 
throughout the body. It is preferentially absorbed in areas 
where cancer has invaded the bone. There the 
radioisotope emits beta particles (electrons) which kill 
the nearby cancer cells. Pain begins to improve in the 
first week for most people and the effects can last several 
months. It is commonly used in lung cancer, prostate 
cancer, breast cancer, and osteosarcoma.12,13 
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Table 1: Drugs used for treatment of disorders of skeletal system 
S. No. Drug Name Uses (Disease) 
1. Norfloxacin Spontaneous tendon ruptures 
2. Cefalexin Bacterial endocarditis (pneumonia, urinary tract inf., bone& joint 
inf., otitis media). 
3. Samarium-153 Palliation (bone cancer). 
4. Samarium(153SM) lexidronam Lung cancer, prostate cancer, breast cancer (Osteosarcoma). 
 
Biocomposites: Bone Cement Composites, 
Hydroxyapatite and Biomimetic Hybrid Composites: 
A biocomposite is a material formed by a matrix (resin) 
and a reinforcement of natural fibers (usually derived 
from plants or cellulose). They often mimic the 
structures of the living materials involved in the process 
in addition to the strengthening properties of the matrix 
that was used but still providing biocompatibility, e.g. in 
creating scaffolds in bone tissue engineering14. 
Biocomposites are characterized by the fact that: 
 the petrochemical resin is replaced by a vegetable or 
animal resin, and/or 
 the bolsters (fiberglass, carbon fiber or talc) are 
replaced by natural fiber (wood fibers, hemp, flax, 
sisal, jute)  
Bone Cement Composites: During the last 5 years bone 
cement materials have grown in popularity and are very 
promising osteoconductive substitutes for bone graft. 
They are prepared like acrylic cements and contain a 
range of powders such as monocalcium phosphate, 
tricalcium phosphate and calcium carbonate, which is 
mixed in a solution of sodium phosphate. These cements 
are produced without polymerization and the reaction is 
nearly non-exothermic. The final compounds are 
reported to have a strength of 10-100 MPa in 
compression while 1-10 MPa in tension, although very 
weak under shear forces. These composites are currently 
used in orthopedics in the management of fractures. 
Injection of calcium phosphate cement has been shown 
to be feasible and it does improve their compressive 
strength. 
Hydroxyapatite Composite Materials: Hydroxyapatite 
cement is a calcium phosphate-based material that when 
mixed with water forms a dense pastes that sets within 
15 minutes and isothermically converts in vivo to a 
micro porous hydroxyapatite implant. Preparation of 
hydroxyapatite/ceramic composites through the addition 
of various ceramic reinforcements has been attempted, 
metal fibers, Si3N4 or hydroxyapatite whiskers, Al2O3 
platelets and ZrO2 particles. Hydroxyapatite/metal and 
hydroxyapatite/polymer composites are two typical 
classes of materials, which have been examined for 
improving the toughness characteristics of synthetic 
hydroxyapatite. In both cases, a toughness improvement 
can be found, due to a crack-face bridging mechanism 
operated upon plastic stretching of metallic or polymeric 
ligaments. Zhang et al. proposed a toughened composite 
consisting of calcium hydroxyapatite dispersed with 
silver particles. This material was obtained by a 
conventional sintering method. It was reported that the 
toughness of these composites increased up to 2.4MPa 
m1/2 upon loading the mixture, with (30 vol. %) silver15.  
Biomimetic Hybrid Composites: The conventional way 
to synthesize an inorganic material-based composite is to 
subject a mixture of the constituent phases to heat 
treatment. Traditional sintering route is not directly 
applicable to produce ceramic/polymer composites 
because no polymer will stand at the densification 
temperature of any ceramic material. 
Hydroxyapatite/polyethylene composites have been 
obtained by loading the polymeric matrix with the 
inorganic filler. In recent years, several research groups 
have demonstrated the feasibility of in vitro techniques 
for the synthesis of biomimetic material structures. A 
common characteristic of natural biomaterials such as 
bone, nacre, sea urchin tooth and other tough hybrid 
materials in nature is the strong microscopic interaction 
between the inorganic and the organic phases. This 
characteristic allows the organic phase to act as a plastic 
energy-dissipating network, forming stretching 
(bridging) ligaments across the faces of a propagating 
crack in a nano-scale level. Such complexity has led to 
the common perception that, to mimic natural designs, in 
situ synthesis techniques should be adopted. Precipitation 
of calcium carbonate or hydroxyapatite into a polymeric 
matrix, for example, has been proposed as a novel 
synthetic route to biomimetic composites. 
APPROACHES FOR SKELETAL DRUG 
DELIVERY SYSTEMS: 
1. Calcium Phosphate Cements As Bone Drug 
Delivery Systems: 
Since calcium phosphate cements were proposed, several 
formulations have been developed, some of them 
commercialized, and they have proven to be very 
efficient bone substitutes in different applications. Some 
of their properties, such as the inject ability, or the low-
temperature setting, which allows the incorporation of 
different drugs, make them very attractive candidates as 
drug carriers.14, 16  
Calcium phosphate: 
Calcium phosphate is the name given to a family of 
minerals containing calcium ions (Ca2+) together with 
orthophosphates (PO4
3-), meta-phosphates or 
pyrophosphates (P2O7
4-) and occasionally hydrogen or 
hydroxide ions. Calcium phosphate is the principal form 
of calcium found in bovine milk. Seventy percent of 
bone consists of hydroxyapatite, a calcium phosphate 
mineral (known as bone mineral). Tooth enamel is 
composed of almost ninety percent hydroxyapatite. 
 Calcium phosphates: 
 Monocalcium phosphate, E341(i): Ca(H2PO4)2 
 Dicalcium phosphate, E341(ii): CaHPO4 
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 Tricalcium phosphate (or tricalcic phosphate), 
E341(iii): Ca3(PO4)2, sometimes referred to simply 
as calcium phosphate or calcium orthophosphate 
 Hydroxyapatite Ca5(PO4)3(OH) 
 Apatite Ca10(PO4)6(OH, F, Cl, Br)2 
 Octacalcium phosphate Ca8H2(PO4)6.5H2O 
2. Calcium Phosphate Cements:  
In the field of the pharmacological treatment of skeletal 
disorders, the specific characteristics of bone tissue 
should be considered. Thus an ideal drug carrier for bone 
should be bioactive, which would ensure the ability of 
the materials to bond to the bone tissue, and resorbable to 
allow its progressive by newly formed bone. Additional 
advantages are provided if the material is injectable, 
since it would improve ease of administration, by 
allowing minimally invasive surgical techniques. All 
these properties are very well fitted by calcium 
phosphate cement, and therefore they should be 
competitive candidates to be used for this application. 
a. CPC as drug carrier material: 
The development of CPC was an important breakthrough 
in the field of bioceramices for bone regeneration, since 
it supplied a material which was mould-able and which 
had the capacity of self-setting in-vivo within the bone 
cavity. Their ability to set once implanted within the 
body, giving a highly microporous material, allows 
incorporation of many types of drugs and biologically 
active molecules, without losing activity and 
denaturalization. Therefore, the possibility to use CPCs 
not only as bone substitutes, but as a carrier for local and 
controlled supply of drugs is very attractive and can be 
useful in treatments of different skeletal diseases, which 
normally require long and painful therapies, as well as 
for accelerating the rate of bone fracture healing.  
Calcium phosphate cements as carriers for antibiotics: 
In the field of application of CPCs for drug delivery, the 
antibiotics have been widely studied, due to their 
frequent use in the treatment of infections of the skeletal 
system, or as a prophylactic strategy. Antibiotics are 
often provided as prophylactics, either orally or 
intravenously. However, the very little accessibility of 
the site of infection very often prolongs the treatment of 
bone infections. A traditional method applied to control 
bone infections is the implantation of poly-
methylmethacrylate spheres (PMMA) loaded with 
gentamicin sulphate in the infection site. 
Calcium phosphate cements as carriers for other drugs: 
anti-inflammatory, analgesic and anticancer: Besides 
their application as antibiotic carriers, CPC can be 
appropriate matrixes for the incorporation of other drugs 
with potential application in the musculoskeletal system. 
Ginebra et al. studied the effect of the incorporation of an 
amino salicylic acid derived methacrylamide in apatitic 
α-TCP-based cement. Salicylic acid is an analgesic and 
anti-inflammatory, and moreover has calcium 
complexation ability. Strong effects were observed both 
in the rheological and mechanical properties. The inject 
ability was improved, but simultaneously a decrease in 
the reaction rate of the cement was observed. 
Calcium phosphate cements as carriers for growth 
factors and other proteins: Growth factors are a large 
group of polypeptides, able to transmit signals which 
affect cellular activity. Among them, the superfamily of 
β-transforming growth factors (TGF β-SF) is especially 
relevant for bone regeneration. It includes the 
transforming growth factors β1, β2, β3 (TGF-β1, β2 and 
β3), and the bone morphogenetic proteins (BMP) among 
other proteins. It is known that they play a role as 
activating agents for the complex cascades of biological 
phenomena responsible for bone formation, and therefore 
they can accelerate bone in growth.15, 16, 17 
3. Essential oils: 
Essential oils also known in the literature as etheric oils 
are fragrant, highly volatile (quickly evaporating in 
contact with air) liquids that are produced naturally in 
specialized glands of aromatic plants, each essential oil 
are a unique energetic being.  
Essential oils are valuable is because they have several 
things in common with human blood. They are accepted 
by the body because of these commonalities. They 
include: compatibility with human proteins, ability to 
fight infection and regenerate tissue, similarity in 
chemical structure with human cells, similar hormone-
like compounds. 
The essential oils used for skeletal systems include - 
Helichrysum, Wintergreen, Peppermint, Idaho Balsam 
Fir, Clove, Peace & Calming, PanAway. 
Rheumatic disease and arthritis in childhood are 
important causes of both short and long term disability. 
Early medical diagnosis and treatment can minimize the 
short and long term evolution of this condition18, 19, 20. 
4. Poultice: 
This ancient, traditional heat treatment soothes and 
alleviates muscle tension using a combination of 
compresses and massage, with specific herbs chosen to 
purify and detoxify the body. By opening the pores of the 
skin, the warm medicinal herbs naturally reduce swelling 
and inflammation of muscles, ligaments and joints.  
However, Bone/Skin Poultice is more than a "fill-in" 
since this supplement provides all the medicinal merits 
of comfrey Bone/Skin Poultice combines yarrow 
flowers, mullein leaf, plantain herb and Chinese 
rehmannia root to give additional benefits not found in 
comfrey alone.  
Herbs Used In Poultice: 
 Plantain: This famous herb helps pull tissues 
together for healing (astringent), is antiseptic and 
diuretic, in addition to cooling, soothing and healing. 
Plantain is excellent for repairing both acute and 
chronic wounds and can be used internally and 
externally. 
 Chinese rehmannia root: In Chinese herbalism this 
root has been used to treat specific conditions such 
as-headaches, migraines, arthritis, rheumatism, flu, 
inflammatory skin conditions and anemia.  
 Mullein leaf: An aid for pain, bleeding and infection, 
mullein leaf is also an anti-spasmodic (relieves 
Kar et al                                           Journal of Drug Delivery & Therapeutics; 2014, 4(3), 60-68     65 
© 2011-14, JDDT. All Rights Reserved                                               ISSN: 2250-1177                                                 CODEN (USA): JDDTAO 
cramps). This herb is famous for lung problems and 
is a wonderful healer, even for swollen tissues 
including the joints.  
 Yarrow flowers: Yarrow contains a blue volatile oil 
that is a powerful anti - inflammatory, so it reduces 
swelling, redness and speeds healing.  
a. Uses of Poultice: 
 Poultice of clay with lemon juice: The poultice of 
clay mixed with lemon juice more or less diluted 
with water as the case has a special power in all the 
"itis", i.e. inflammation with evident pain, including 
arthritis and the like. 
 Poultice of clay with purple grape juice: The black 
grape is always preferable to white. The large 
amount of tannin contained in the creditor makes a 
special place in trofoterapia and the same here, 
geoterapia or cure for the land. If we use placed on 
the heart area is an excellent tonic, like if we apply it 
on the spine or joints will be an active regenerating 
skeletal system, i.e. the bones.  
5. Plaster: 
There are several different kinds of plaster casting 
material available. The choice depends on the particular 
injury. In a Stable fracture the cast is often only needed 
to protect the bone from further injury and limit 
movement a little at the fracture site. (A little movement 
stimulates healing; too much movement slows it down). 
Hence the molding and fit is not as critical. It is also 
possible to make a removable cast or use pre made 
splints. In an unstable fracture treated just with a cast, 
here the plaster cast is critical in holding the bone ends in 
a good position and as such the fit and molding is very 
important22, 23, 24. 
Following an acute fracture swelling can be a problem 
and as such a: 
a. Backslab: "Backslab" is used; this does not have to 
go on the back of the limb. This is 
made up of an under layer of orthopaedic wool, with 
a slab of usually old fashioned white plaster of paris. 
It does not encircle the limb, usually covering half or 
3/4rs of the circumference of the limb. A bandage is 
applied to keep it well applied to the limb. The "cut 
away" completed by the bandage allows for 
swelling. "Backslabs" are usually temporary, used 
for a few days. They usually do not last longer than 
2 weeks. 
b. Plaster of Paris (Gypsum): Plaster of paris is often 
used in acute, fresh fractures. The reason Plaster of 
paris (Gypsum) is often used in this setting, is 
because it is a lot easier to mould to get a snug fit 
without creating any pressure areas. It is heavier 
than and not as resilient as synthetic casts but still 
the preferred casting material for fractures requiring 
a snug fit and "molding" over the fracture to keep 
the bones in a good position 
c. Synthetic casts: Often called fibreglass casts, this is 
a slight misnomer not all synthetic casts are made of 
fiber glass, and some are made of polyester. There 
are two main synthetic casting groups. 
Hard casts and soft casts- Softcasts are used mostly for 
support or stable fractures in kids. Benefits of softcast 
include the ability to remove by unwrapping or cutting 
off the cast without the need for a plaster saw. It is also 
possible to manufacture a "swimming cast" using 
softcast. 
d. Swimming cast: Plaster of paris (Gypsum) should 
not be placed in water it softens the cast and it will 
disintegrate. Synthetic casts (hard) will normally not 
fall apart if they get wet or splashed. The problem is 
the padding or underlay remains wet for a long time 
and the skin may macerate. If you do get your hard 
synthetic cast moist or wet dry it out with a 
hairdryer. 
e. Looking after swimming cast: The problem with 
swimming softcasts and water is not that the cast 
will disintegrate but that the skin will become soggy 
and macerate. Flush out the limb with clean water to 
get rid of any dirt and wash out any pool chemicals. 
Dry out the limb if not in a warm climate use a hair 
dryer and ensure the cast dries totally. Give the skin 
a break does not keep it soaked in water all the time.            
6. Lepa: The preparation in the form of paste meant 
for external application on the body is known as 
lepa. The crude drug in the powdered form are 
mixed with cow urine, water, oil or ghee and made 
into paste. Lepas prepared from vegetable powders 
are stable only for one month, while lepas 
containing minerals or metals long last. 
Example: Sinduradi lepa, Pathyadi lepa, Dasanga 
lepa and Dosaghna lepa. 
 
7. Ointments: A highly viscous or semisolid substance 
used on the skin as a cosmetic, emollient, or 
medicament. Ointment is, any greasy substance 
rubbed on the skin to heal injuries.  
NOVEL APPROACHES FOR SKELETAL DRUG 
DELIVERY SYSTEMS: 
1. Self-Setting Hydroxypatite Cement: 
To solve the problem of delivering drugs to skeletal 
tissue at high enough local concentrations for desirable 
therapeutic effects, a novel approach using a self-setting 
hydroxyapatite cement, with cephalexin and norfloxacin 
as model drugs is reported. After setting, the cement was 
transformed into hydroxyapatite with affinity for hard 
bone tissue. Continuous in-vitro drug release profiles 
from loaded cement pellets (0.9-4.8% by weight) in 
phosphate buffer at pH 7.4 and 37 degrees C followed 
the Higuchi equation. A novel approach using a self-
setting hydroxyapatite (HAP) cement as a skeletal drug-
delivery system has been proposed to solve the problem 
of delivering drugs to skeletal tissue at sufficiently high 
local concentrations for desirable therapeutic effects. 
HAP cements loaded with antibiotics can be formed in 
situ and can be used as bonding materials between bone 
and prostheses, as well as drug-release devices. The 
cement also possesses sufficient mechanical strength to 
be a potential bone grafting material. Using cephalexin 
and norfloxacin as model drugs, continuous in vitro 
release profiles of these compounds from cement pellets 
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loaded 0.9-4.8% by weight with one of the drugs is 
observed. This drug-release pattern correlated well with 
the Higuchi model. This hydroxyapatite cement drug-
delivery system can be applied in the treatment of 
osteomyelitis and infected compound fractures.25,26 
2. Bone Specific-Drug Delivery System: 
Bone-specific drug delivery systems approache via 
chemical modification of bone-seeking agents. Despite 
several decades of progress, bone-specific delivery is 
still limited by the unique anatomical features of bone, 
which mainly consists of inorganic hydroxyapatite. A 
practical approach to this problem is to produce targeted 
drugs that have a high affinity for hydroxyapatite. 
Bisphosphonates are a class of synthetic compounds 
structurally related to pyrophosphate. Bisphosphonates 
rapidly localize on the bone surface after being 
administered either intravenously or orally, since the P-
C-P portion of the bisphosphonate structure has high 
affinity for hydroxyapatite. Therefore, bisphosphonate 
modification might be a promising method for targeting 
drugs selectively to the bone. Bisphosphonate-
conjugated drugs are hydrophilic and highly water-
soluble due to the acidic nature of the bisphosphonate 
moiety at physiological pH, and therefore they hardly 
permeate through the biological membrane of soft 
tissues. These physicochemical changes also reduce the 
intrinsic susceptibility of the drug to metabolism, 
promoting urinary or biliary excretion as unchanged 
drug. All these physicochemical and pharmacokinetic 
alterations contribute to the exceptional skeletal 
disposition of bisphosphonate-conjugated drugs. 
Although most examples of bone-specific drug delivery 
via bone-seeking agents still remain in preclinical 
studies, several phosphonate-coupled 
radiopharmaceuticals, such as samarium-153 complexes 
to tetraphosphonate, are expected to be effective pain 
palliation therapies for metastatic bone cancer and are 
currently being developed in clinical trials. Furthermore, 
recent reports on bisphosphonate-modified proteins have 
illustrated the feasibility of bone-specific delivery of 
biologically active protein drugs, such as cytokines and 
growth factors. 17 
3. Hydrogels in Calcium Phosphate Moldableand 
Injectable Bone Substitute: 
As a consequence of trauma, disease and degeneration, 
the need for bone grafts is constantly growing. The 
limitations of auto-grafts consist mainly in explant site 
pain and morbidity, and limited availability. Allo and 
xeno-grafts can overcome these limitations, but the risk 
of immune reactions and, in some countries, limited 
availability of tissue banks, patient compliance and 
regulatory restrictions are major hurdles at present. In 
this respect, synthetic bone substitutes (SBSs) based on 
calcium phosphate (CaP) materials are valid alternatives 
to tissue transplants, and their clinical use dates back 
more than a century. In the context of this paper, besides 
compounds synthesized via solution chemistry, thermal 
synthesis and thermal decomposition, CaPs also include 
semi-synthetic minerals such as deproteinized bovine 
bone.19  
4. Bone Grafts: 
There are four characteristics that an ideal bone graft 
material should exhibit which include: 
 Osteointegration, the ability to chemically bond to 
the surface of bone without an intervening layer of 
fibrous tissue; 
 Osteoconduction, the ability to support the growth of 
bone over its surface; 
 Osteoinduction, the ability to induce differentiation 
of pluripotential stem cells from surrounding tissue 
to an osteoblastic phenotype;  
 Osteogenesis, the formation of new bone by 
osteoblastic cells present within the graft material. 
Only autogenous bone graft satisfies all of these 
requirements. Allograft is osteointegrative and 
osteoconductive and may exhibit osteoinductive 
potential, but it is not osteogenic because it contains no 
live cellular component. Synthetic bone graft substitutes 
currently possess only osteointegrative and 
osteoconductive properties. A variety of artificial 
materials has been used over the centuries to fill bone 
defects. Synthetic bone grafts at most possess only two 
of the four characteristics of an ideal bone graft material 
(osteointegration, osteoconduction). 
 Bioactive glasses: Two families of silicon-based 
compounds have the ability to bond directly to bone, 
bioactive glasses and the glass ionomers. Bioactive 
glasses are hard, solid (non-porous), materials that 
were first described in the 1970s. They consist of 
sodium oxide, calcium oxide, phosphorus pentoxide 
and silicon dioxide. Silicon dioxide (also known as 
silicate) forms the main component. Bioactive 
glasses possess both osteointegrative and 
osteoconductive properties.  
 Glass ionomers: Glass ionomer cements were first 
introduced in 1971 for dental use where cement was 
required to bind tooth enamel in a moist 
environment. The paste sets hard in approximately 5 
min after which it is water insoluble. Prior to this it 
must be protected from wound fluids which will 
dissolve it. 
 Aluminium oxide: Alumina (Al2O3) is a component 
of several bioactive materials but can serve as a 
bone graft substitute on its own. A mechanical bond 
occurs as a result of stresses on the implant that 
bring it into intimate relationship with the 
surrounding bone. 
 Calcium sulfate: Calcium sulfate is actually plaster 
of Paris. It was first documented as being used for 
fracture treatment by the Arabs in the 10th century, 
who would surround the affected limb in a tub of 
plaster. In 1852 a Dutch army surgeon by the name 
of Mathysen incorporated plaster into a bandageable 
forms (the form with which we are familiar today). 
Calcium sulfate is thought to act as an 
osteoconductive matrix for the ingrowth of blood 
vessels and associated fibrogenic and osteogenic 
cells.  
a. Antibiotic Beads: 
Antibiotic beads are both a complementary and 
alternative treatment option to intravenous antibiotic 
therapy for the treatment of osteomyelitis. 
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Polymethylmethacrylate (PMMA) antibiotic beads were 
introduced clinically 30 years ago and have been the 
main local antibiotic delivery system in osteomyelitis 
therapy until recently. Polymethylmethacrylate antibiotic 
beads serve two functions in the treatment of 
osteomyelitis. Following surgical debridement of 
osteomyelitis, antibiotic-impregnated PMMA beads are 
surgically placed in the infected bone cavity to both 
sterilize and maintain dead space in the bone. Clearly, 
the use of antibiotic PMMA beads alone in osteomyelitis 
therapy offers several advantages. Studies reported these 
beads produce negligible to no systemic antibiotic serum 
concentrations, thereby leading to decreased systemic 
toxicity and adverse effects. Antibiotic-impregnated 
PMMA beads also decrease hospitalization duration and 
overall treatment cost. By eliminating the need for 
intravenous (IV) access, they also may increase both 
patient comfort and early ambulation. The use of PMMA 
as a delivery vehicle for antibiotic beads are non-
biodegradable. 
b. Biodegradable Local Drug Delivery Systems: 
New biodegradable drug delivery systems in 
development and testing offer hope in improving 
treatment for osteomyelitis. These new systems do not 
necessitate removal and should therefore eliminate the 
need for a second surgery. They will still serve to 
maintain the dead space in the bone and some may help 
facilitate new bone formation. 
a. Polylactic Acid: 
Polylactic acid (PLA) has been used for structural 
support following orthopedic procedures for years and 
has recently been studied as a delivery system for 
antibiotics. Previous use in humans for this purpose has 
produced rare adverse effects including non-infected 
draining sinuses and non-infected local inflammatory 
responses. The clinical significance of these adverse 
effects currently is unclear. 
b. Calcium Sulfate: 
Calcium sulfate is a promising vehicle that is 
biodegradable, obliterates dead space, and may aid in 
new bone formation. Animal model studies have 
assessed efficacy and safety, and early preliminary 
studies have been conducted in humans. 
5. Injectable Drug Delivery: 
The past decade has seen a dramatic shift in terms of the 
types of approved injectable drugs, the diseases they 
target, and the devices used to deliver them such as 
injectables bone cements for spinal coloum 
augmentation. The principal goal of applying these 
injectable bone cements is to augment impaired bony 
structures in order to maintain or improve the strength 
and stability of the spinal column. Currently, many new 
injectable bone cements are being designed specifically 
for application in the vertebral body. 23 
6. Nanoparticles as a Tool For the Treatment of 
Skeletal System Disorders: 
In nanotechnology, a particle is defined as a small object 
that behaves as a whole unit with respect to its transport 
and properties. Particles are further classified according 
to diameter. Ultrafine particles or nanoparticles are sized 
between 1 and 100 nanometers. The reason for this 
double name of the same object is that, during the 1970-
80's, when the first thorough fundamental studies with 
"nanoparticles" were underway in the USA (by 
Granqvist and Buhrman) and Japan, (within an ERATO 
Project) they were called "ultrafine particles" (UFP).   
Polymer nanoencapsulated rare earth aerogels- Rare 
earth (RE) aerogels combine the typical high porosity of 
aerogels with useful electrical, magnetic, optical and 
catalytic properties of the skeletal framework. RE 
aerogels are prepared by supercritical fluid CO2 drying of 
wet gels.  
CONCLUSIONS 
Skeletal drug delivery systems can be used to treat local 
and systemic diseases. The novel advancements in 
skeletal drug delivery with respect to materials, carriers 
and dosage forms open a wide era for development of 
better therapeutic dosage forms while minimising the 
drug, dose and the dosage. These will enhance the patient 
compliance for a much suitable therapeutic effect of the 
drug. 
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